Formulation and Evaluation of Floating Tablets of RHCL Using Natural and Synthetic Polymers

Kavita.K, Sudhir K. Yadav*, Tamizhamani T

1Department of Pharmaceutics, Bharathi College of Pharmacy, Bharathi Nagara, Maddur Taluk, Mandya Dist., Karnataka - 571 422, India

Department of Pharmaceutics, Bharathi College of Pharmacy, Bharathinagara, K.M. Doddi, Maddur, dist-Mandya, Karnataka –571422, India

*Corresponding Author: sudhir.yadav83@gmail.com, Tel: +91-9980636287

ABSTRACT: The purpose of this research was to prepare a floating drug delivery system of Ranitidine hydrochloride (RHCL) in order to increase the gastric residence time (GRT) and comparison of natural and synthetic polymer for better sustained effect. The tablets were prepared by direct compression. The drug: polymer interaction was determined by IR spectroscopic method. Pre and post compression studies were performed by using IP standard formula and procedure. Drug release from the floating drug delivery system was studied using USP II. The release behavior of the natural and synthetic polymer was compared according to obtained data. The release data were subjected to different models zero order, first order Higuchi and Pappas in order to evaluate their release kinetics and mechanisms. The hardness of all formulations was found to be in the range of 3.5±0.2 - 4.5±0.1 kg/cm2. Among these all formulations (F1 to F4) prepared by direct compression, batch F4 was best formulation and showed very slow release i.e. 76.02% in 12 h (p < 0.05). The drug release of the other formulation like F1 to F3 (94.79%, 88.73%, 83.32% in 12h) was higher from the F1 formulation prepared by direct compression. The drug release was observed by fickian diffusion mechanism. The release kinetics of the formulation F1and F2 (synthetic polymer) shows more release as compare to F3 and F4 (natural polymer). Natural polymer shows better sustained release properties than synthetic polymer. The formulation with guar gum and xanthum gum shows better sustained release effect than HPMC different grade. The developed floating tablets of RHCL may be used in clinic for prolonged drug release for at least 12hrs, thereby improving the bioavailability and patient compliance.

KEYWORDS RHCL, gastroretentive, floating drug delivery, sustained release.

INTRODUCTION

Despite tremendous advancements in drug delivery the oral route remains the preferred route of administration of therapeutic agents because of low cost of therapy and ease of administration lead to high levels of patient compliance. But the issue of poor bioavailability (BA) of orally administered drugs is still a challenging one, though extensive advancements in drug discovery process are made. Gastric emptying is a complex process and makes in vivo performance of the drug delivery systems uncertain. In order to avoid this variability, efforts have been made to increase the retention time of the drug-delivery systems for more than 12 hours. The floating or hydrodynamically controlled drug delivery systems are useful in such application. Ranitidine hydrochloride (RHCL) is a histamine H2-receptor antagonist. It is widely prescribed in active duodenal ulcers, gastric ulcers, Zollinger-Ellison syndrome, gastroesophageal reflux disease, and erosive esophagitis. The recommended adult oral dosage of ranitidine is 150 mg twice daily or 300 mg once daily. The effective treatment of erosive esophagitis requires administration of 150 mg of ranitidine 4 times a day. A conventional dose of 150 mg can inhibit gastric acid secretion up to 5 hours but not up to 10 hours. An alternative dose of 300 mg leads to plasma fluctuations; thus a sustained release dosage form of
RHCl is desirable. The short biological half-life of drug (~2.5-3 hours) also favors development of a sustained release formulation. A traditional oral sustained release formulation releases most of the drug at the colon, thus the drug should have absorption window either in the colon or throughout the gastrointestinal tract. Ranitidine is absorbed only in the initial part of the small intestine and has 50% absolute bioavailability. Moreover, colonic metabolism of ranitidine is partly responsible for the poor bioavailability of ranitidine from the colon. These properties of RHCl do not favor the traditional approach to sustained release delivery. Hence, clinically acceptable sustained release dosage forms of RHCl prepared with conventional technology may not be successful. The gastroretentive drug delivery systems can be retained in the stomach and assist in improving the oral sustained delivery of drugs that have an absorption window in a particular region of the gastrointestinal tract. These systems help in continuously releasing the drug before it reaches the absorption window, thus ensuring optimal bioavailability.

It is also reported that oral treatment of gastric disorders with an H2-receptor antagonist like ranitidine or famotidine used in combination with antacids promotes local delivery of these drugs to the receptor of the parietal cell wall. Local delivery also increases the stomach wall receptor site bioavailability and increases the efficacy of drugs to reduce acid secretion. Several approaches are currently used to prolong gastric retention time. These include floating drug delivery systems, also known as hydrodynamically balanced systems, swelling and expanding systems, polymeric bioadhesive systems, modified-shape systems, high-density systems, and other delayed gastric emptying devices. The principle of buoyant preparation offers a simple and practical approach to achieve increased gastric residence time for the dosage form and sustained drug release. In context of the above principles, a strong need was recognized for the development of gastroretentive RHCl dosage forms.

Floating drug delivery systems offer important advantages: as they are less prone to gastric emptying resulting in reduced intra and intersubject variability in plasma drug levels, effective for delivery of drugs with narrow absorption windows, reduced dosing and increased patient compliance, reduced Cmax and prolonged drug levels above the minimum effective concentration, and improved safety profile for drugs with side-effects associated with high Cmax.

**EXPERIMENTAL MATERIALS**

Ranitidine HCL was received as a gift sample from Karnataka Antibiotics, Bangalore India. Hydroxypropylmethylcellulose (HPMC) K4M, K100M and Guar gum, Xanthum gum were obtained as a gift sample from Karnataka Antibiotics Ltd. Bangalore and Shreeji chemicals, Mumbai.

**METHODS**

**PREPARATION OF RHCL FLOATING TABLETS**

RHCl was dispersed in chloroformic solution of the required quantity of stearic acid. The dispersion was stirred and chloroform was evaporated to form an RHCl-stearic acid mixture. This mixture was then blended with other ingredients such as polymer, sodium bicarbonate and citric acid. The powder blend was then lubricated with magnesium stearate (1% wt/wt) and purified talc (1% wt/wt) and compressed on single punch tablet machine.

**DRUG: POLYMER INTERACTION STUDY**

The pure drug and prepared floating tablet were subjected to IR spectroscopic study using FT-IR spectrophotometer (IRAffinity-1, Shimadzu). The spectra were scanned over the wave number range from 4000 – 400 cm⁻¹. The pellet press techniques were used for sample testing.

**EVALUATION OF POWDER BLENDS**

**ANGLE OF REPOSE**

The angle of repose of powder blend was determined by the funnel method. The accurately weight powder blend were taken in the funnel. The height of the funnel was adjusted in such a way the tip of the funnel just touched the apex of the powder blend. The powder blend was allowed to flow through the funnel freely on to the surface. The diameter of the powder cone was measured and angle of repose was calculated using the following equation.

\[
\tan \theta = \frac{h}{r}
\]

Where, h and r are the height and radius of the powder cone.
BULK DENSITY
Both loose bulk density (LBD) and tapped bulk density (TBD) was determined. A quantity of 2 gm of powder blend from each formula, previously shaken to break any agglomerates formed, was introduced in to 10 ml measuring cylinder. After that the initial volume was noted and the cylinder was allowed to fall under its own weight on to a hard surface from the height of 2.5 cm at second intervals. Tapping was continued until no further change in volume was noted. LBD and TBD were calculated using the following equations.

\[
\text{LBD} = \frac{\text{Weight of powder blend}}{\text{untapped volume of the packing}}
\]

\[
\text{TBD} = \frac{\text{Weight of the powder blend}}{\text{Tapped Volume of the packing}}
\]

COMPRESSIBILITY INDEX
The Compressibility Index of the powder blend was determined by Carr’s compressibility index. It is a simple test to evaluate the LBD and TBD of a powder and the rate at which it packed down. The formula for Carr’s Index is as below:

\[
\text{Carr}’\text{’s index} = \frac{\text{TBD} - \text{LBD}}{\text{TBD}} \times 100
\]

FLOATING PROPERTIES OF THE TABLET
(FLOATING LAG TIME)
The time taken for tablet to emerge on surface of medium is called the floating lag time (FLT) and duration of time the dosage form to constantly remain on surface of medium is called the total floating time (TFT). The in vitro buoyancy was determined by floating lag time, per the method described by Rosa et al. The tablets were placed in a 100-mL beaker containing 0.1N HCl. The time required for the tablet to rise to the surface and float was determined as floating lag time.

PERCENTAGE DRUG CONTENT STUDY
Drug content was determined by dissolving sustained release granules equivalent to 100 mg of RHCL in 70 ml of distilled water. It was shaken for 15 min. and then diluted to 100 ml with distilled water. It was filtered through Whatman filter paper no. 41. One ml of this solution was transferred to 10 ml volumetric flask and final volume was made 10 ml. Absorbance of the resulting solution was measured at 315 nm. The drug content was determined by referring to the calibration curve.

IN VITRO DISSOLUTION STUDIES
The release rate of RHCl from floating tablets was determined using United States Pharmacopeia (USP) I. Dissolution Testing Apparatus 2 (paddle method). The dissolution test was performed using 900 ml of 0.1N HCl, at 37 ±0.5°C and 75 rpm. A sample (10 ml) of the solution was withdrawn from the dissolution apparatus hourly for 12 hours, and the samples were replaced with fresh dissolution medium. The samples were filtered and diluted to a suitable concentration with 0.1N HCl. Absorbance of these solutions was measured at 315 nm using a Shimadzu UV-1800 UV/Vis double-beam spectrophotometer (Electro lab, TDT-08L). Cumulative percentage drug release was calculated using an equation obtained from a standard curve.

STATISTICAL ANALYSIS
The Statistical analysis was performed using Graph Pad InStat3 software. All the parameters were run 3 times (n=3) except the pre-compression parameter. Experimental results were expressed as mean ± SD., Student’s t-test and one-way analysis of variance (ANOVA) were applied to check significant differences in mean of post-compression parameter, %Cumulative Release, Zero order, First order, Higuchi kinetics, Peppas Equation between batch series ‘F1’ and batch ‘F2’. Differences were considered to be statistically significant at p < 0.05.

RESULTS
DRUG POLYMER INTERACTION STUDY
Drug- excipient interactions play a vital role with respect to release of drug from the formulation amongst others. FTIR techniques have been used here to study the physical and chemical interaction between drug and excipients used. In the present study, it has been observed that there is no chemical interaction between RHCL and the polymers used. Drug has given peaks due to furan ring, secondary diamine, alkene and two peaks due to nitro functional groups. Form the figure it was observed that there were no changes in these main peaks in IR spectra of mixture of drug and polymers, which show there were no physical interactions because of some bond formation between drug and polymers.

PRE-COMPRESSION EVALUATION
The granules of various formulations containing drug and polymer were evaluated for the angle of repose, loose bulk density(LBD), tapped bulk density(TBD) , void volume, bulkiness, total porosity and Compressibility(Carr’s) index given in Table 2. The angles of repose for all formulations were found to be in the range of 25-30° indicating excellent flow properties. The values for LBD and TBD were found to be in the range of 0.52 to 0.67 g/cm³ and 0.68 to
0.79 g/cm³ indicating good packing capacity. Carr’s indexes for all formulations were found to be in the range of 15.18 to 24% indicating excellent flow properties, cohesiveness.

**POST-COMPRESSION EVALUATION**

Tablets of each formulation type (F1 to F4) were evaluated for parameters such as thickness, diameter, weight variation, drug content, hardness and friability given in Table 3. The weight of all formulation tablets were within the range according to IP. The hardness was in range of 3.5-4.5 kg/cm². Friability was found to be 0.69 – 0.82%. As friability was below 1% tablets in each formulation can withstand the mechanical shocks. Percentage drug content in formulations F1 to F4 were found to be in the range of 95-100%. It showed uniform distribution of drug.

**FLOATING BEHAVIOR OF THE TABLETS**

The floating tablets of RHCl with the synthetic polymer (HPMC) shows better floating lag time (37 F1 and 29 second F2) and it was floated up to 12 hrs, and formulation with natural polymers shows more floating lag time (90, 120second F3 and F4 respectively) but it was floated more than 12 hrs.

**DISSOLUTION PROFILE OF THE ALL FORMULATION OF THE RHCL**

The in vitro release of all batches of floating tablets showed the release with an initial effect. In the first hour % drug released were 12.16±1.010, 09.30±0.100, 09.33±0.110, 8.59±0.480, for FT1, FT2, FT3 and FT4 respectively. The % drug release of the all formulation was found to be 94.79±1.020, 88.73±1.013, 83.32±1.110 and 76.02±1.014, for FT1, FT2, FT3 and FT4 respectively. The natural polymers showed more sustained effects as compared to synthetic polymers.

**DRUG RELEASE KINETICS**

The drug release data were explored for the type of release mechanism followed. The best fit with the highest determination r² coefficients was shown by both the zero order and Higuchi models. Zero order release describes the release rate independent of drug concentration. Higuchi square root kinetic model describes, release drug from the insoluble matrix as square root of time dependent process. It describes release of drug by simple diffusion mechanism. The value of n with regression coefficient for all the formulations is shown in Table 3. The values of n were in the range of 0.4907 to 0.5312 (n is more than 0.5) indicating Nonfickian release governed by the drug diffusion. However as indicated by the values of r² both of the models (Higuchi and Peppas) were found to be efficient in describe the release of RHCL from the floating tablets. All the parameters were run 3 times (n=3). The difference in mean of Zero order, First order, Higuchi kinetics and Peppas Equation between batch series ‘F1’ and batch ‘F4’ was indicating significant (p < 0.05).

---

**Table 1: Composition of Tablet**

<table>
<thead>
<tr>
<th>INGREDIENTS</th>
<th>F1</th>
<th>F2</th>
<th>F3</th>
<th>F4</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPMC K4M</td>
<td>90</td>
<td>90</td>
<td>90</td>
<td>90</td>
</tr>
<tr>
<td>HPMC K100M</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Xanthum gum</td>
<td>50</td>
<td>50</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>Guar gum</td>
<td></td>
<td>90</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodiumbicarbonate</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Stearic acid</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Mg. stearate (%)</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Talc (%)</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

Each formulation contains 336 mg of RHCL

---

**Table 2: Pre-compression evaluation of RHCL floating tablets**

<table>
<thead>
<tr>
<th>Formulation code</th>
<th>Angle of Repose* (°)±SD</th>
<th>Loose Bulk Density* (g/cm³) ± SD</th>
<th>Tapped Bulk Density* (g/cm³) ± SD</th>
<th>Carr’s Index* (%)±SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>27.00±0.57</td>
<td>0.59±0.02</td>
<td>0.77±0.017</td>
<td>24.00±0.30</td>
</tr>
<tr>
<td>F2</td>
<td>25.00±0.59</td>
<td>0.61±0.25</td>
<td>0.73±0.006</td>
<td>16.44±0.021</td>
</tr>
<tr>
<td>F3</td>
<td>28.57±0.38</td>
<td>0.52±0.15</td>
<td>0.68±0.52</td>
<td>23.00±0.20</td>
</tr>
<tr>
<td>F4</td>
<td>26.10±0.12</td>
<td>0.67±0.11</td>
<td>0.79±0.004</td>
<td>15.18±0.09</td>
</tr>
</tbody>
</table>

# All the values are expressed as mean ± SD= standard deviation (n=3). Were preparations was significant (p<0.05).
Table 3: Post-compression evaluation of RHCl floating tablets

<table>
<thead>
<tr>
<th>Formulation code</th>
<th>Thickness* (mm)±SD</th>
<th>Hardness* (kg/cm²)±SD</th>
<th>Friability* (%)±SD</th>
<th>Tablet Weight* (mg)±SD</th>
<th>Drug Content* (%)±SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>4 ± 0.2</td>
<td>4.0±0.1</td>
<td>0.82±0.04</td>
<td>555.11±2.34</td>
<td>95.34</td>
</tr>
<tr>
<td>F2</td>
<td>4 ± 0.2</td>
<td>3.5±0.2</td>
<td>0.92±0.06</td>
<td>557.80±1.84</td>
<td>97.37</td>
</tr>
<tr>
<td>F3</td>
<td>4 ± 0.2</td>
<td>4.2±0.1</td>
<td>0.69±0.05</td>
<td>556.63±2.14</td>
<td>98.47</td>
</tr>
<tr>
<td>F4</td>
<td>4 ± 0.2</td>
<td>4.5±0.1</td>
<td>0.71±0.01</td>
<td>556.11±2.24</td>
<td>96.97</td>
</tr>
</tbody>
</table>

* All the values are expressed as mean ± SD = standard deviation (n=3). Where preparations was significant (p<0.05).

Table 4: In Vitro drug release Kinetics of floating tablets of RHCL

<table>
<thead>
<tr>
<th>Formulation code</th>
<th>% Cumulative Release r²</th>
<th>Zero order r²</th>
<th>First order r²</th>
<th>Higuchi kinetics r²</th>
<th>Peppas Equation n</th>
<th>Peppas Equation r²</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>94.79</td>
<td>0.9819</td>
<td>0.8845</td>
<td>0.9033</td>
<td>0.5201</td>
<td>0.8980</td>
</tr>
<tr>
<td>F2</td>
<td>88.73</td>
<td>0.8845</td>
<td>0.8017</td>
<td>0.8297</td>
<td>0.4907</td>
<td>0.8278</td>
</tr>
<tr>
<td>F3</td>
<td>83.32</td>
<td>0.9848</td>
<td>0.8854</td>
<td>0.9035</td>
<td>0.5194</td>
<td>0.8351</td>
</tr>
<tr>
<td>F4</td>
<td>76.02</td>
<td>0.9918</td>
<td>0.8965</td>
<td>0.9061</td>
<td>0.5312</td>
<td>0.9123</td>
</tr>
</tbody>
</table>

Fig: 1 compatibility study (Where A- Pure drug B- Physical mixer of drug and polymer)
Fig 2: Effect of different polymer on in vitro release of formulation F1 (●), F2 (■), F3 (▲) and F4 (●●) of RHCL. Floating tablets

DISCUSSION
The precompression evaluation like bulk density, true density, compressibility, angle of repose were found as per standard range all the data indicating suitable formulation of the floating tablet. The post compression evaluation for the all formulation is complies with the standard monograph. The post compression parameters like hardness, friability, thickness, drug content. The obtained data was best fitted for the floating tablet. The drug release data were explored for the type of release mechanism followed. The best fit with the highest determination \( r^2 \) coefficients was shown by both the zero order and Higuchi models. Zero order release describes the release rate independent of drug concentration. Higuchi square root kinetic model describes, release drug from the insoluble matrix as square root of time dependent process. It describes release of drug by simple diffusion mechanism. The values of n with regression coefficient for all the formulations were showed in the table 4. The values of n were in the range (n is more than 0.5) indicating Nonfickian release governed by the drug diffusion. However as indicated by the values of R2 both of the models (Higuchi and Peppas) were found to be efficient in describe the release of RHCL from the floating tablets. All the parameters were run 3 times (n=3). The difference in mean of Zero order, First order, Higuchi kinetics and Peppas Equation between batch series ‘FT1’ and batch ‘FT4’ was indicating significant (p < 0.05).

CONCLUSION
This study discusses the preparation of gastroretentive tablets of RHCl. The effervescent-based floating drug delivery was a promising approach to achieve in vitro buoyancy. The addition of gel-forming polymer HPMC K4M, natural polymer and gas-generating agent sodium bicarbonate was essential to achieve in vitro buoyancy. Addition of citric acid, to achieve buoyancy under the elevated pH of the stomach, caused an enhancement in drug release that was retarded by incorporation of stearic acid in the formulation. The release kinetics of the formulation F1 and F2 shows more release as compare to F3 and F4.natural polymer shows better sustained release properties than synthetic polymer.

ACKNOWLEDGMENT
Authors are heartily thankful to Bharathi college of Pharmacy Management, for providing facilities to carry out this work and thankful to Micro lab ltd. for providing gift sample of RHCL.

REFERENCES
9. Patel V.F., Patel N.M. Statistical evaluation of influence of viscosity of polymer and type of filler